UBS Group AG Has $2.82 Million Stock Position in Inspire Medical Systems, Inc. (NYSE:INSP)

UBS Group AG increased its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP – Get Rating) by 8.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,884 shares of the company’s stock after purchasing an additional 1,214 shares during the period. UBS Group AG owned approximately 0.05% of Inspire Medical Systems worth $2,817,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Inspire Medical Systems by 1.6% in the first quarter. Vanguard Group Inc. now owns 2,601,849 shares of the company’s stock valued at $667,870,000 after purchasing an additional 42,110 shares in the last quarter. FMR LLC lifted its holdings in shares of Inspire Medical Systems by 7.9% in the second quarter. FMR LLC now owns 2,255,907 shares of the company’s stock valued at $412,087,000 after purchasing an additional 164,645 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Inspire Medical Systems by 0.9% during the second quarter. Macquarie Group Ltd. now owns 1,540,495 shares of the company’s stock worth $281,402,000 after acquiring an additional 14,017 shares during the period. Invesco Ltd. lifted its holdings in Inspire Medical Systems by 9.8% during the first quarter. Invesco Ltd. now owns 885,306 shares of the company’s stock worth $227,249,000 after acquiring an additional 78,975 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in Inspire Medical Systems by 7.5% during the first quarter. Wellington Management Group LLP now owns 632,988 shares of the company’s stock worth $162,482,000 after acquiring an additional 43,924 shares during the period. Institutional investors and hedge funds own 97.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on INSP. JPMorgan Chase & Co. lifted their price target on Inspire Medical Systems from $271.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, February 8th. KeyCorp raised their target price on Inspire Medical Systems from $287.00 to $303.00 and gave the stock an “overweight” rating in a research report on Friday, January 13th. Lake Street Capital raised their target price on Inspire Medical Systems from $250.00 to $305.00 in a research report on Wednesday, February 8th. The Goldman Sachs Group raised Inspire Medical Systems from a “neutral” rating to a “buy” rating and raised their target price for the stock from $245.00 to $308.00 in a research report on Tuesday, December 13th. Finally, Truist Financial raised their target price on Inspire Medical Systems from $310.00 to $330.00 and gave the stock a “buy” rating in a research report on Wednesday, February 8th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $303.00.

Inspire Medical Systems Stock Up 2.0 %

Shares of INSP stock opened at $264.26 on Monday. Inspire Medical Systems, Inc. has a 12-month low of $142.74 and a 12-month high of $282.31. The business has a 50-day moving average price of $256.57 and a two-hundred day moving average price of $223.03. The firm has a market cap of $7.68 billion, a P/E ratio of -161.13 and a beta of 1.47.

Inspire Medical Systems (NYSE:INSP – Get Rating) last released its earnings results on Tuesday, February 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.64. Inspire Medical Systems had a negative return on equity of 12.66% and a negative net margin of 11.00%. The company had revenue of $137.90 million during the quarter, compared to analyst estimates of $137.75 million. During the same quarter in the previous year, the company posted ($0.09) EPS. Inspire Medical Systems’s revenue for the quarter was up 75.9% on a year-over-year basis. As a group, research analysts expect that Inspire Medical Systems, Inc. will post -1.32 EPS for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, COO Philip Ebeling sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $275.00, for a total transaction of $1,925,000.00. Following the transaction, the chief operating officer now owns 243 shares in the company, valued at approximately $66,825. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Philip Ebeling sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $275.00, for a total value of $1,925,000.00. Following the transaction, the chief operating officer now directly owns 243 shares of the company’s stock, valued at approximately $66,825. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Timothy P. Herbert sold 2,619 shares of the company’s stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $275.05, for a total value of $720,355.95. Following the completion of the transaction, the chief executive officer now directly owns 9,728 shares in the company, valued at $2,675,686.40. The disclosure for this sale can be found here. Insiders sold 68,678 shares of company stock valued at $17,441,298 in the last 90 days. Insiders own 5.00% of the company’s stock.

Inspire Medical Systems Company Profile

(Get Rating)

Inspire Medical Systems, Inc engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead.